BR112020009219A2 - derivados de ácido cafeico e usos dos mesmos - Google Patents

Info

Publication number

BR112020009219A2

BR112020009219A2 BR112020009219-3A BR112020009219A BR112020009219A2 BR 112020009219 A2 BR112020009219 A2 BR 112020009219A2 BR 112020009219 A BR112020009219 A BR 112020009219A BR 112020009219 A2 BR112020009219 A2 BR 112020009219A2

Authority

BR

Brazil

Prior art keywords

compound

fact

cancer

cooh

groups

Prior art date

2017-11-10

Links

• Espacenet
• Global Dossier
• Discuss

• QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 title abstract description 14
• 150000001875 compounds Chemical class 0.000 claims abstract description 194
• 238000000034 method Methods 0.000 claims abstract description 61
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 48
• 201000011510 cancer Diseases 0.000 claims abstract description 31
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
• 238000011282 treatment Methods 0.000 claims abstract description 25
• -1 hydroxy, amino Chemical group 0.000 claims description 57
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
• 201000010099 disease Diseases 0.000 claims description 43
• 125000003118 aryl group Chemical group 0.000 claims description 39
• 229910052739 hydrogen Inorganic materials 0.000 claims description 33
• 239000001257 hydrogen Substances 0.000 claims description 33
• 150000003839 salts Chemical class 0.000 claims description 32
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 31
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 17
• 125000001072 heteroaryl group Chemical group 0.000 claims description 15
• 125000000304 alkynyl group Chemical group 0.000 claims description 14
• 125000001246 bromo group Chemical group Br* 0.000 claims description 14
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
• 201000009030 Carcinoma Diseases 0.000 claims description 11
• 208000035475 disorder Diseases 0.000 claims description 11
• 150000002431 hydrogen Chemical group 0.000 claims description 11
• 229910052760 oxygen Inorganic materials 0.000 claims description 11
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 10
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 10
• 125000005843 halogen group Chemical group 0.000 claims description 10
• 230000003463 hyperproliferative effect Effects 0.000 claims description 10
• 201000001441 melanoma Diseases 0.000 claims description 10
• 125000003545 alkoxy group Chemical group 0.000 claims description 9
• 239000000460 chlorine Substances 0.000 claims description 9
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 9
• 125000001769 aryl amino group Chemical group 0.000 claims description 8
• 229910052717 sulfur Inorganic materials 0.000 claims description 8
• 206010025323 Lymphomas Diseases 0.000 claims description 7
• 125000003282 alkyl amino group Chemical group 0.000 claims description 7
• 125000004104 aryloxy group Chemical group 0.000 claims description 7
• 210000000481 breast Anatomy 0.000 claims description 7
• 208000032839 leukemia Diseases 0.000 claims description 7
• 210000004072 lung Anatomy 0.000 claims description 7
• 125000002757 morpholinyl group Chemical group 0.000 claims description 7
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 7
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 6
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
• 206010039491 Sarcoma Diseases 0.000 claims description 6
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
• 210000003128 head Anatomy 0.000 claims description 6
• 210000003734 kidney Anatomy 0.000 claims description 6
• 210000004185 liver Anatomy 0.000 claims description 6
• 210000000496 pancreas Anatomy 0.000 claims description 6
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
• 210000002307 prostate Anatomy 0.000 claims description 6
• 210000003491 skin Anatomy 0.000 claims description 6
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
• 210000004369 blood Anatomy 0.000 claims description 5
• 239000008280 blood Substances 0.000 claims description 5
• 210000004556 brain Anatomy 0.000 claims description 5
• 210000001072 colon Anatomy 0.000 claims description 5
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid group Chemical group C(\C=C/C(=O)O)(=O)O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
• 201000005962 mycosis fungoides Diseases 0.000 claims description 5
• 210000003739 neck Anatomy 0.000 claims description 5
• 210000001672 ovary Anatomy 0.000 claims description 5
• 210000002784 stomach Anatomy 0.000 claims description 5
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
• 210000000988 bone and bone Anatomy 0.000 claims description 4
• 210000003679 cervix uteri Anatomy 0.000 claims description 4
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
• 210000003238 esophagus Anatomy 0.000 claims description 4
• 239000011976 maleic acid Substances 0.000 claims description 4
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
• 208000017520 skin disease Diseases 0.000 claims description 4
• 210000001550 testis Anatomy 0.000 claims description 4
• 206010027406 Mesothelioma Diseases 0.000 claims description 3
• 208000034578 Multiple myelomas Diseases 0.000 claims description 3
• 201000004681 Psoriasis Diseases 0.000 claims description 3
• 210000000867 larynx Anatomy 0.000 claims description 3
• 210000000813 small intestine Anatomy 0.000 claims description 3
• 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
• 201000010208 Seminoma Diseases 0.000 claims description 2
• 229910052794 bromium Inorganic materials 0.000 claims description 2
• 210000003169 central nervous system Anatomy 0.000 claims description 2
• 210000004696 endometrium Anatomy 0.000 claims description 2
• 210000000232 gallbladder Anatomy 0.000 claims description 2
• 210000004392 genitalia Anatomy 0.000 claims description 2
• 210000002429 large intestine Anatomy 0.000 claims description 2
• 210000002200 mouth mucosa Anatomy 0.000 claims description 2
• 210000003205 muscle Anatomy 0.000 claims description 2
• 210000002850 nasal mucosa Anatomy 0.000 claims description 2
• 210000000952 spleen Anatomy 0.000 claims description 2
• 210000001685 thyroid gland Anatomy 0.000 claims description 2
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 5
• IPBNQYLKHUNLQE-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid;azane Chemical compound [NH4+].C=12C(S(=O)(=O)[O-])=CC=CC2=CC=CC=1NC1=CC=CC=C1 IPBNQYLKHUNLQE-UHFFFAOYSA-N 0.000 claims 1
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
• 241000689227 Cora <basidiomycete fungus> Species 0.000 claims 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
• 229910052801 chlorine Inorganic materials 0.000 claims 1
• 239000000203 mixture Substances 0.000 description 49
• 229910052799 carbon Inorganic materials 0.000 description 47
• 210000004027 cell Anatomy 0.000 description 41
• 239000003607 modifier Substances 0.000 description 33
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
• 125000004429 atom Chemical group 0.000 description 28
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 27
• 230000003211 malignant effect Effects 0.000 description 27
• 235000002639 sodium chloride Nutrition 0.000 description 27
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 26
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
• 239000003814 drug Substances 0.000 description 23
• 125000000217 alkyl group Chemical group 0.000 description 20
• 150000001721 carbon Chemical class 0.000 description 20
• 239000000047 product Substances 0.000 description 20
• 230000001225 therapeutic effect Effects 0.000 description 19
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
• 230000015572 biosynthetic process Effects 0.000 description 18
• 238000003786 synthesis reaction Methods 0.000 description 18
• 125000004432 carbon atom Chemical group C* 0.000 description 17
• 229940079593 drug Drugs 0.000 description 17
• 230000000670 limiting effect Effects 0.000 description 17
• 241000282414 Homo sapiens Species 0.000 description 16
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 15
• 239000011541 reaction mixture Substances 0.000 description 15
• 239000000243 solution Substances 0.000 description 15
• 210000004881 tumor cell Anatomy 0.000 description 15
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 239000012043 crude product Substances 0.000 description 11
• 229910052757 nitrogen Inorganic materials 0.000 description 11
• 239000000651 prodrug Substances 0.000 description 11
• 229940002612 prodrug Drugs 0.000 description 11
• 125000006413 ring segment Chemical group 0.000 description 11
• 239000002904 solvent Substances 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 10
• 239000004480 active ingredient Substances 0.000 description 9
• 125000001931 aliphatic group Chemical group 0.000 description 9
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
• 125000004122 cyclic group Chemical group 0.000 description 8
• 230000007170 pathology Effects 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• 101100113485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chs-3 gene Proteins 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 125000002252 acyl group Chemical group 0.000 description 7
• 208000009956 adenocarcinoma Diseases 0.000 description 7
• 150000001336 alkenes Chemical class 0.000 description 7
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 7
• 125000003636 chemical group Chemical group 0.000 description 7
• 239000003937 drug carrier Substances 0.000 description 7
• 238000003756 stirring Methods 0.000 description 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 6
• 102000004495 STAT3 Transcription Factor Human genes 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 239000008186 active pharmaceutical agent Substances 0.000 description 6
• 125000002015 acyclic group Chemical group 0.000 description 6
• 230000002354 daily effect Effects 0.000 description 6
• 239000003480 eluent Substances 0.000 description 6
• 238000010828 elution Methods 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 208000008443 pancreatic carcinoma Diseases 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 101150009057 JAK2 gene Proteins 0.000 description 5
• 206010027476 Metastases Diseases 0.000 description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 125000003342 alkenyl group Chemical group 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 230000009401 metastasis Effects 0.000 description 5
• 125000004433 nitrogen atom Chemical class N* 0.000 description 5
• 201000002528 pancreatic cancer Diseases 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• 150000001335 aliphatic alkanes Chemical class 0.000 description 4
• 125000000732 arylene group Chemical group 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 230000000694 effects Effects 0.000 description 4
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
• 239000012091 fetal bovine serum Substances 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
• 125000006574 non-aromatic ring group Chemical group 0.000 description 4
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 4
• 150000002894 organic compounds Chemical class 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000011593 sulfur Substances 0.000 description 4
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 206010003571 Astrocytoma Diseases 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• AUUBHCRBERYWSW-UHFFFAOYSA-N N(=[N+]=[N-])C(CC)(CC)C1=CC=C(C=C1)OCCOCCCl Chemical compound N(=[N+]=[N-])C(CC)(CC)C1=CC=C(C=C1)OCCOCCCl AUUBHCRBERYWSW-UHFFFAOYSA-N 0.000 description 3
• LQGFOYZSOMLIKG-XTQSDGFTSA-N N1(CCN(C)CC1)CCOCCOC1=CC=C(C=C1)C(NC(=O)/C(=C/C1=NC(Cl)=CC=C1)/C#N)(CC)CC Chemical compound N1(CCN(C)CC1)CCOCCOC1=CC=C(C=C1)C(NC(=O)/C(=C/C1=NC(Cl)=CC=C1)/C#N)(CC)CC LQGFOYZSOMLIKG-XTQSDGFTSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 125000003368 amide group Chemical group 0.000 description 3
• 230000001640 apoptogenic effect Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 239000002274 desiccant Substances 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
• 238000012377 drug delivery Methods 0.000 description 3
• 235000019441 ethanol Nutrition 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
• 230000036210 malignancy Effects 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000011580 nude mouse model Methods 0.000 description 3
• 239000000575 pesticide Substances 0.000 description 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 208000000649 small cell carcinoma Diseases 0.000 description 3
• 201000011549 stomach cancer Diseases 0.000 description 3
• 125000000547 substituted alkyl group Chemical group 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 238000010189 synthetic method Methods 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• KTQQCTXAHKGZMX-UHFFFAOYSA-N 1-[4-[2-(2-chloroethoxy)ethoxy]phenyl]propan-1-one Chemical compound CCC(=O)C1=CC=C(OCCOCCCl)C=C1 KTQQCTXAHKGZMX-UHFFFAOYSA-N 0.000 description 2
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 208000005243 Chondrosarcoma Diseases 0.000 description 2
• 101150065749 Churc1 gene Proteins 0.000 description 2
• ICJHUWPJJHNRBP-LSDHQDQOSA-N ClC1=CC=CC(=N1)/C=C(/C(=O)NC(CCC)(CCC)C1=CC=C(C=C1)OCCN1CCOCC1)\C#N Chemical compound ClC1=CC=CC(=N1)/C=C(/C(=O)NC(CCC)(CCC)C1=CC=C(C=C1)OCCN1CCOCC1)\C#N ICJHUWPJJHNRBP-LSDHQDQOSA-N 0.000 description 2
• HMVBCMICEUMTFB-UHFFFAOYSA-N ClCCOCCOC1=CC=C(C=C1)C(CC)(CC)O Chemical compound ClCCOCCOC1=CC=C(C=C1)C(CC)(CC)O HMVBCMICEUMTFB-UHFFFAOYSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 206010014967 Ependymoma Diseases 0.000 description 2
• 208000006168 Ewing Sarcoma Diseases 0.000 description 2
• 201000008808 Fibrosarcoma Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 208000001258 Hemangiosarcoma Diseases 0.000 description 2
• 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 208000018142 Leiomyosarcoma Diseases 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 206010027145 Melanocytic naevus Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 201000010133 Oligodendroglioma Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 102100038239 Protein Churchill Human genes 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 102100027981 Septin-7 Human genes 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 150000007824 aliphatic compounds Chemical class 0.000 description 2
• 150000001345 alkine derivatives Chemical class 0.000 description 2
• 125000001118 alkylidene group Chemical group 0.000 description 2
• 230000002707 ameloblastic effect Effects 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 150000001491 aromatic compounds Chemical class 0.000 description 2
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000002784 cytotoxicity assay Methods 0.000 description 2
• 231100000263 cytotoxicity test Toxicity 0.000 description 2
• 239000000412 dendrimer Substances 0.000 description 2
• 229920000736 dendritic polymer Polymers 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 201000003914 endometrial carcinoma Diseases 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 125000003709 fluoroalkyl group Chemical group 0.000 description 2
• 230000003325 follicular Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 150000002390 heteroarenes Chemical class 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 2
• 150000002440 hydroxy compounds Chemical class 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 125000001841 imino group Chemical group [H]N=* 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000001965 increasing effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 229940126601 medicinal product Drugs 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
• 208000025113 myeloid leukemia Diseases 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 210000001989 nasopharynx Anatomy 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 201000010198 papillary carcinoma Diseases 0.000 description 2
• 208000007312 paraganglioma Diseases 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 239000003090 pesticide formulation Substances 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 238000003419 tautomerization reaction Methods 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 210000002105 tongue Anatomy 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
• AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
• ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
• SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
• WPPUHFMHKVHECR-UHFFFAOYSA-N 1-[4-(2-bromoethoxy)phenyl]butan-1-one Chemical compound CCCC(=O)C1=CC=C(OCCBr)C=C1 WPPUHFMHKVHECR-UHFFFAOYSA-N 0.000 description 1
• IADFYSLRLWUKCF-UHFFFAOYSA-N 1-[4-(2-bromoethoxy)phenyl]propan-1-one Chemical compound CCC(=O)C1=CC=C(OCCBr)C=C1 IADFYSLRLWUKCF-UHFFFAOYSA-N 0.000 description 1
• UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
• NSFIAKFOCAEBER-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylphenyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(O)(C(O)=O)C(O)(C(O)=O)C1=CC=C(C)C=C1 NSFIAKFOCAEBER-UHFFFAOYSA-N 0.000 description 1
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
• YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
• AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
• 208000004804 Adenomatous Polyps Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 241001120493 Arene Species 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000035821 Benign schwannoma Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 1
• 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000007690 Brenner tumor Diseases 0.000 description 1
• 206010073258 Brenner tumour Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
• RNDHRCHYUIAPKV-UHFFFAOYSA-N C(#N)CC(=O)NC(CC)(CC)C1=CC=C(C=C1)OCCN(CC)CC Chemical compound C(#N)CC(=O)NC(CC)(CC)C1=CC=C(C=C1)OCCN(CC)CC RNDHRCHYUIAPKV-UHFFFAOYSA-N 0.000 description 1
• YLOVZJRUZOPWFO-UHFFFAOYSA-N C(#N)CC(=O)NC(CC)(CC)C1=CC=C(C=C1)OCCN1CCOCC1 Chemical compound C(#N)CC(=O)NC(CC)(CC)C1=CC=C(C=C1)OCCN1CCOCC1 YLOVZJRUZOPWFO-UHFFFAOYSA-N 0.000 description 1
• WULMDJJHOAFEPI-UHFFFAOYSA-N C(#N)CC(=O)NC(CC)(CC)C1=CC=C(C=C1)OCCOCCN1CCOCC1 Chemical compound C(#N)CC(=O)NC(CC)(CC)C1=CC=C(C=C1)OCCOCCN1CCOCC1 WULMDJJHOAFEPI-UHFFFAOYSA-N 0.000 description 1
• VRAGWVPJFPODHP-UHFFFAOYSA-N C(#N)CC(=O)NC(CCC)(CCC)C1=CC=C(C=C1)OCCN(CC)CC Chemical compound C(#N)CC(=O)NC(CCC)(CCC)C1=CC=C(C=C1)OCCN(CC)CC VRAGWVPJFPODHP-UHFFFAOYSA-N 0.000 description 1
• JCIYPDGZMPUZPC-UHFFFAOYSA-N C(#N)CC(=O)NC(CCC)(CCC)C1=CC=C(C=C1)OCCN1CCOCC1 Chemical compound C(#N)CC(=O)NC(CCC)(CCC)C1=CC=C(C=C1)OCCN1CCOCC1 JCIYPDGZMPUZPC-UHFFFAOYSA-N 0.000 description 1
• IPSYMADXCQGHFY-UHFFFAOYSA-N C(C)N(CCOC1=CC=C(C=C1)C(CC)(CC)N)CC Chemical compound C(C)N(CCOC1=CC=C(C=C1)C(CC)(CC)N)CC IPSYMADXCQGHFY-UHFFFAOYSA-N 0.000 description 1
• GVQOQRBZEMNLFD-UHFFFAOYSA-N C(C)N(CCOC1=CC=C(C=C1)C(CCC)(CCC)N)CC Chemical compound C(C)N(CCOC1=CC=C(C=C1)C(CCC)(CCC)N)CC GVQOQRBZEMNLFD-UHFFFAOYSA-N 0.000 description 1
• PBZFROOOFRSAJB-UHFFFAOYSA-N CCCC(CCC)(N=[N+]=[N-])C1=CC=C(OCCN2CCN(C)CC2)C=C1 Chemical compound CCCC(CCC)(N=[N+]=[N-])C1=CC=C(OCCN2CCN(C)CC2)C=C1 PBZFROOOFRSAJB-UHFFFAOYSA-N 0.000 description 1
• ODKZTJFONLUKFX-UHFFFAOYSA-N CCCC(CCC)(N=[N+]=[N-])c1ccc(OCCBr)cc1 Chemical compound CCCC(CCC)(N=[N+]=[N-])c1ccc(OCCBr)cc1 ODKZTJFONLUKFX-UHFFFAOYSA-N 0.000 description 1
• 208000032325 CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome Diseases 0.000 description 1
• OGYHODZDQPCFRE-UHFFFAOYSA-N CN1CCN(CC1)CCOC1=CC=C(C=C1)C(CCC)(CCC)N Chemical compound CN1CCN(CC1)CCOC1=CC=C(C=C1)C(CCC)(CCC)N OGYHODZDQPCFRE-UHFFFAOYSA-N 0.000 description 1
• DCRDWQZGFPKZRZ-UHFFFAOYSA-N CN1CCN(CC1)CCOCCOC1=CC=C(C=C1)C(CC)(CC)N Chemical compound CN1CCN(CC1)CCOCCOC1=CC=C(C=C1)C(CC)(CC)N DCRDWQZGFPKZRZ-UHFFFAOYSA-N 0.000 description 1
• 101150003532 CSH gene Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 201000000274 Carcinosarcoma Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 206010008583 Chloroma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• COOUJNZICIHBTQ-CZIZESTLSA-N ClC1=CC=CC(=N1)/C=C(/C(=O)NC(CC)(CC)C1=CC=C(C=C1)OCCN(CC)CC)\C#N Chemical compound ClC1=CC=CC(=N1)/C=C(/C(=O)NC(CC)(CC)C1=CC=C(C=C1)OCCN(CC)CC)\C#N COOUJNZICIHBTQ-CZIZESTLSA-N 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
• 208000007033 Dysgerminoma Diseases 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
• 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
• 206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 208000031852 Gastrointestinal stromal cancer Diseases 0.000 description 1
• 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
• 208000002125 Hemangioendothelioma Diseases 0.000 description 1
• 208000006050 Hemangiopericytoma Diseases 0.000 description 1
• 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 108010019437 Janus Kinase 2 Proteins 0.000 description 1
• 102000006503 Janus Kinase 2 Human genes 0.000 description 1
• 201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010024218 Lentigo maligna Diseases 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 206010024305 Leukaemia monocytic Diseases 0.000 description 1
• 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
• 208000000265 Lobular Carcinoma Diseases 0.000 description 1
• 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• 238000000719 MTS assay Methods 0.000 description 1
• 231100000070 MTS assay Toxicity 0.000 description 1
• 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
• 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• ZXCYMIJDMIFWCZ-UHFFFAOYSA-N N(=[N+]=[N-])C(CC)(CC)C1=CC=C(C=C1)OCCBr Chemical compound N(=[N+]=[N-])C(CC)(CC)C1=CC=C(C=C1)OCCBr ZXCYMIJDMIFWCZ-UHFFFAOYSA-N 0.000 description 1
• ZMRKARHTWHSPQD-UHFFFAOYSA-N N(=[N+]=[N-])C(CC)(CC)C1=CC=C(OCCN2CCOCC2)C=C1 Chemical compound N(=[N+]=[N-])C(CC)(CC)C1=CC=C(OCCN2CCOCC2)C=C1 ZMRKARHTWHSPQD-UHFFFAOYSA-N 0.000 description 1
• BWGSEEFIQXZALB-UHFFFAOYSA-N N(=[N+]=[N-])C(CC)(CC)C1=CC=C(OCCOCCN2CCOCC2)C=C1 Chemical compound N(=[N+]=[N-])C(CC)(CC)C1=CC=C(OCCOCCN2CCOCC2)C=C1 BWGSEEFIQXZALB-UHFFFAOYSA-N 0.000 description 1
• UHBOQMVTBOJRBN-UHFFFAOYSA-N N(=[N+]=[N-])C(CCC)(CCC)C1=CC=C(OCCN2CCOCC2)C=C1 Chemical compound N(=[N+]=[N-])C(CCC)(CCC)C1=CC=C(OCCN2CCOCC2)C=C1 UHBOQMVTBOJRBN-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 206010029488 Nodular melanoma Diseases 0.000 description 1
• AAJKAJRYQJXONB-UHFFFAOYSA-N O1CCN(CC1)CCOC1=CC=C(C=C1)C(CCC)(CCC)N Chemical compound O1CCN(CC1)CCOC1=CC=C(C=C1)C(CCC)(CCC)N AAJKAJRYQJXONB-UHFFFAOYSA-N 0.000 description 1
• HUXOIQWFHBUBPM-UHFFFAOYSA-N O1CCN(CC1)CCOCCOC1=CC=C(C=C1)C(CC)(CC)N Chemical compound O1CCN(CC1)CCOCCOC1=CC=C(C=C1)C(CC)(CC)N HUXOIQWFHBUBPM-UHFFFAOYSA-N 0.000 description 1
• 208000007871 Odontogenic Tumors Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 208000009077 Pigmented Nevus Diseases 0.000 description 1
• 208000019262 Pilomatrix carcinoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
• 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 208000032383 Soft tissue cancer Diseases 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
• 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 206010070863 Toxicity to various agents Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000006336 acinar cell carcinoma Diseases 0.000 description 1
• 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 125000004442 acylamino group Chemical group 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 125000005035 acylthio group Chemical group 0.000 description 1
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
• 201000000452 adenoid squamous cell carcinoma Diseases 0.000 description 1
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
• 201000005179 adrenal carcinoma Diseases 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 125000006323 alkenyl amino group Chemical group 0.000 description 1
• 125000003302 alkenyloxy group Chemical group 0.000 description 1
• 125000000033 alkoxyamino group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 125000006319 alkynyl amino group Chemical group 0.000 description 1
• 125000005133 alkynyloxy group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
• 208000006431 amelanotic melanoma Diseases 0.000 description 1
• 208000010029 ameloblastoma Diseases 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 201000007580 appendix carcinoma Diseases 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 201000005476 astroblastoma Diseases 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 201000007551 basophilic adenocarcinoma Diseases 0.000 description 1
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• WWVKQTNONPWVEL-VQHVLOKHSA-N benzyl (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-VQHVLOKHSA-N 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000012925 biological evaluation Methods 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 208000007047 blue nevus Diseases 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 201000011143 bone giant cell tumor Diseases 0.000 description 1
• 201000006491 bone marrow cancer Diseases 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 201000003714 breast lobular carcinoma Diseases 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• 239000006189 buccal tablet Substances 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 235000004883 caffeic acid Nutrition 0.000 description 1
• 229940074360 caffeic acid Drugs 0.000 description 1
• WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 238000002737 cell proliferation kit Methods 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 201000002891 ceruminous adenocarcinoma Diseases 0.000 description 1
• 208000024188 ceruminous carcinoma Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 201000005217 chondroblastoma Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
• 229940125797 compound 12 Drugs 0.000 description 1
• 229940126543 compound 14 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 150000001924 cycloalkanes Chemical class 0.000 description 1
• 125000000000 cycloalkoxy group Chemical group 0.000 description 1
• 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 125000001240 enamine group Chemical group 0.000 description 1
• 150000002081 enamines Chemical class 0.000 description 1
• 239000008393 encapsulating agent Substances 0.000 description 1
• 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 125000002587 enol group Chemical group 0.000 description 1
• 210000003237 epithelioid cell Anatomy 0.000 description 1
• 201000010877 epithelioid cell melanoma Diseases 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 210000004195 gingiva Anatomy 0.000 description 1
• 201000002264 glomangiosarcoma Diseases 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 201000007574 granular cell carcinoma Diseases 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 125000005241 heteroarylamino group Chemical group 0.000 description 1
• 125000005553 heteroaryloxy group Chemical group 0.000 description 1
• 208000029824 high grade glioma Diseases 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 125000000879 imine group Chemical group 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 208000025095 immunoproliferative disease Diseases 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
• 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 125000003473 lipid group Chemical group 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 208000025036 lymphosarcoma Diseases 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 150000002689 maleic acids Chemical class 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 208000018013 malignant glomus tumor Diseases 0.000 description 1
• 201000004102 malignant granular cell myoblastoma Diseases 0.000 description 1
• 201000006812 malignant histiocytosis Diseases 0.000 description 1
• 206010061526 malignant mesenchymoma Diseases 0.000 description 1
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
• 201000002338 malignant struma ovarii Diseases 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 208000000516 mast-cell leukemia Diseases 0.000 description 1
• 201000008749 mast-cell sarcoma Diseases 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 201000010225 mixed cell type cancer Diseases 0.000 description 1
• 208000029638 mixed neoplasm Diseases 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000007479 molecular analysis Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 201000006894 monocytic leukemia Diseases 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 201000005987 myeloid sarcoma Diseases 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000002121 nanofiber Substances 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 229910052754 neon Inorganic materials 0.000 description 1
• GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
• 208000029974 neurofibrosarcoma Diseases 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 201000000032 nodular malignant melanoma Diseases 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 208000027825 odontogenic neoplasm Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
• 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 201000002628 peritoneum cancer Diseases 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical group CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 208000031223 plasma cell leukemia Diseases 0.000 description 1
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
• 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
• 208000013368 pseudoglandular squamous cell carcinoma Diseases 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 238000010926 purge Methods 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
• 201000003804 salivary gland carcinoma Diseases 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000002078 skin pilomatrix carcinoma Diseases 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 239000002594 sorbent Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 229960004274 stearic acid Drugs 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 208000028210 stromal sarcoma Diseases 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• 208000030457 superficial spreading melanoma Diseases 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960001367 tartaric acid Drugs 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 208000001644 thecoma Diseases 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 125000003441 thioacyl group Chemical group 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000723 toxicological property Toxicity 0.000 description 1
• 208000029335 trabecular adenocarcinoma Diseases 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 239000006163 transport media Substances 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000000277 virosome Substances 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000004711 α-olefin Substances 0.000 description 1